Is it relevant a correct intimate cleansing in the treatment of vulvar dermatosis? ()
2. MATERIALS AND METHODS
The experimental design was a controlled, randomized, clinical study in which 32 patients with vulvar dermatoses were recruited. The diagnosis was either of LS or LSC. Each patient received Mometasone furoate in the form of 0.1% cream. The treatment was intensive during the first month. It consisted of the use of 1/2 fingertip unit (FTU), i.e. the amount of topical Mometasone furoate that is squeezed out from a standard tube on the fingertip of an adult (that is about 0.5 g of topical steroid) once a day for four weeks, then twice a week for four more weeks and subsequently topical steroid was applied only when needed as a rescue treatment. We then divided the patients in two Groups according to the randomization list: Group A: the patients were prescribed to use the cleanser A twice a day in association with one application of lanolin cream daily for 30 days, following which the lanolin cream was applied only when needed as a rescue treatment. The cleaner A was a non-irritant cleaner based on specific substances with cleansing, hydrating, antimicrobial and anti-inflammatory properties (amigdalus dulcis, malva, jojoba oil, PCL solid, Hyaluronic acid). Group B: the patients were prescribed to use the cleanser B in association with one application of lanolin cream daily for 30 days, and after that the lanolin cream was applied only when needed as a rescue treatment. The cleaner B was a non-irritant cleaner based on soft natural surfactants (Cocoyl Wtheat Amino Acids) and with hydrating and emollient substances (Maltodextrins, Aveena sativa, Caprylic Glycol).
The parameters evaluated for efficacy were the following: amount of the rescue cream used, rubbing, applicability and pleasantness of the product. Each descriptor was ranked on a 4-point intensity scale (0 = none, 1 = mild, 2 = moderate and 3 = severe). The signs and symptoms were classified before and after 60 days of treatment. A statistical analysis for the comparison of the two treatments was carried out by applying the chisquare test (improved vs impaired/unchanged versus baseline) and Student’s t test (amount of rescue cream employed).
3. RESULTS
The characteristics of the study population are summarized in Table 1. The women in the two groups were similar for age (52 years, range 32 - 73 for cleanser A vs 56 years, range 34 - 69 for cleanser B) and diagnosis.
The differences between the two treatments for rubbing, applicability and pleasantness of the product were statistically non-significant (Figure 1).
The dryness was quantified indirectly through the average number of applications of Lanolin cream as a rescue treatment. The “as needed” use of the emollient lanolin cream was significantly superior in a total number of doses in the B group versus the A group (8.25 vs 5.28 (P < 0.001).
4. DISCUSSION
A Vulvar dermatoses are mainly treated with topical ste-
Table 1. Characteristics of the study populations.
Figure 1. Symptoms after treatment. °Days; *Score 0 - 3 (0 = none, 1 = mild, 2 = moderate and 3 = severe), means P value: cream at need = 0.001, rubbing = 0.05, applicability = 0.03 pleasentness = 0.06.
roids to relieve the symptoms, prevent structural damages and to reverse histologic changes. The recommended regimen for LS and LSC, the most frequent vulvar dermatosis, begins with a high-potency corticosteroid used daily until the resolution of active lesions after which it is tapered to once or twice per week [8]. A gradual dose reduction enables the majority of patients to remain in asymptomatic remission and minimizes the steroid exposure [9].
In vulvar dermatosis problems related to the damage of the barrier function of vulvar skin can arise. The skin barrier depends on the degree of hydration, the presence of a horny/corneum layer and an intact surface. The surface lipid film is the main vulvar skin protective factor. It consists of a hydrophilic component (Natural Moisturizing Factor = NMF) and a soluble fraction, mainly consisting of sebum. Treatment of vulvar dermatoses should be aimed to restore the lipid film surface to protect the vulvar skin which requires the need of using emollient preparations in addition to topical steroid therapy and specific products for personal hygiene [10].
In our study we compared two different cleaners as adjuvants in the treatment of vulvar dermatoses. The parameters, namely applicability and acceptability/pleasantness, showed a high score for both the cleansers, demonstrating the acceptability of these products by the women and hence, an increase in the compliance.
Both cleansers show a strong activity in limiting the vulvar rubbing (cleaner A versus cleaner B, 0.75 versus 1.44, p = 0.02); even though the higher activity which occured with cleaner A had a borderline significance, but this difference in favor of the cleaner A is clinically important, as it was achieved despite the B cleaner group applied a significantly higher number of doses of emollient cream as a rescue treatment. The rubbing is an indirect index of friction and that of the superficial dryness. This emphasizes the moisturizing properties of the two products. The number of days required for the application of the moisturizing cream on demand, is the most different parameter in the two groups of patients (A = 5.38 days; B = 8:25 days) with an average that is statistically significant (p = 0.001), and in any case low for both groups.
The best results of the cleaner A can be attributed to not only the pool of moisturizing and emollient active ingredients but that of the soothing as well.
This shows how the role of intimate cleanser is not only for the cleansing of vulva, but can also play a therapeutic role of moisturization and emollience. This is aimed at restoration of the skin surface lipid film, compromised in vulvar dermatoses where the interruption of skin barrier effect increases dehydration and promotes the onset of rigidity and superficial erosions, supporting the persistence of vulvar itching and burning. This appears even more evident if the cleanser has specific active ingredients distinctly moisturizing, soothing and decongestant (Cleaner A).
In order to soothe, clean and protect the external mucosa in an eudermic fashion the cleanser should not contain alkaline and occlusive substances as well as anionic surfactants. It should clean by affinity and contain ingredients that are complementary and synergic.
Specific active ingredients of Cleaner A are: Amygdalus dulcis that contains high percentages of fatty acids with special eurdermic properties:jojoba oil, that is an anti-inflammatory and emollient that stimulates the cutaneous circulation; the Hyaluronic acid that is able to incorporate large quantities of water maintaining the degree of moisturization, turgidity, plasticity and viscosity. Hyaluronic acid acts like a cementing, anti-collision substance as well as an efficient lubrificant thus, preventing the damage of tissue by the physical stress. It also acts like a filter against the free diffusion of certain substances, bacteria and infecting agents in the tissue; European aloe: the unsaponifiable fraction strongly attracted to the skin sebum performs protetive and sebum substituting functions. It acts on the skin trophism stimulating the repairing processes in the derma and epidermis; the solid PCL, another active ingredient of cleaner A, has significant moisturizing and film-forming properties, that are particularly active in recreating the protective film surface.
5. CONCLUSION
This new-generation intimate cleanser was effective in reducing burning and providing a concomitant emollience in the treatment of vulvar dermatoses. In particular, the product acts by “affinity” and not by “contrast” like the most surfactant based foaming cleansers. Again we stress the need for a proper hygiene with selected products that meet the vulvar skin requirements.